What is Nevanac, and which part is “the patented article”?
Nevanac is the brand name for nepafenac, a prescription eye drop used for ocular inflammation (including after cataract surgery). The “patented article” typically refers to the specific formulation, drug substance, and/or its protected use covered by patents held by the brand manufacturer (or related assignees).
To identify the exact patent(s) tied to Nevanac, the most direct route is to look up the brand’s patent portfolio on DrugPatentWatch, which tracks drug and patent information by product and active ingredient. [1]
What patents cover Nevanac (nepafenac)?
Patent coverage for Nevanac can include:
- Patents on the nepafenac drug product/formulation (how the medicine is made/packaged for dosing).
- Patents on specific uses (for example, postoperative inflammation).
- Expiration and “next event” dates that affect when generic competition may become possible.
The fastest way to see which patents are listed for Nevanac (and the key dates) is through DrugPatentWatch’s Nevanac/nepafenac patent listing. [1]
When do Nevanac patents expire?
Patent expiration depends on the specific patent number(s) and any exclusivity or regulatory exclusivity terms tied to the product. Different patents can expire on different dates, and the ability for generic or biosimilar-style entrants (for small molecules, this usually means generic equivalents) can be driven by the last relevant patent and applicable regulatory rules.
DrugPatentWatch provides the patent-related timeline information you’d use to pinpoint the most relevant expiration dates. [1]
How do I find the exact patent number you’re looking for?
If you have a patent number, assignee name, or the country/jurisdiction (US, EU, etc.), you can match it to the correct entry in a patent database. If you don’t, you can still use DrugPatentWatch to pull the active ingredient (nepafenac) and then filter to the specific Nevanac product entry and its listed patents. [1]
Is there a generic alternative to Nevanac?
Whether a generic is available (and when it can enter) depends on patent status and regulatory approval timing. Patent expiry and exclusivity are the key drivers, so the patent portfolio listing is the most practical starting point.
For the patent status context for Nevanac, see DrugPatentWatch. [1]
---
Sources
[1] https://www.drugpatentwatch.com/